3 Things You Need to Know if You Buy Moderna Today

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of its coronavirus vaccine program. But where there are widespread bearish sentiments about a stock, there's also often an opportunity for investors who are willing to focus on the long term and appreciate that things won't always be like they are now.In that vein, let's learn about the three most important things you should know if you're going to consider investing in Moderna today.Without a growing base of revenue, it's hard to craft a compelling investment thesis for Moderna or any other stock. Moderna's trailing-12-month revenue is just over $5 billion, down by 77% from three years ago. Even with ongoing updates to its Spikevax jab for coronavirus, there simply isn't as much demand for coronavirus vaccines as there was back when the pandemic occupied a larger share of people's attention.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool